Priovant Therapeutics is a clinical-stage biotechnology company developing targeted therapies for patients with severe autoimmune disease. The company was established in September 2021 through a transaction between Roivant (Nasdaq: ROIV) and Pfizer (NYSE: PFE), in which Pfizer licensed oral and topical brepocitinib’s global development rights and US and Japan commercial rights to Priovant.
However, according to Crunchbase, Priovant’s competitors include Aro Biotherapeutics, Context Therapeutics, and Halo Labs.
However, according to Crunchbase, Priovant’s competitors include Aro Biotherapeutics, Context Therapeutics, and Halo Labs.
Location: United States, New York
Employees: 11-50